Strategic focus Target market opportunities exist in oncology hospital systems and research centers that could adopt Canady Plasma technology for post-surgical tumor treatment to minimize recurrence and preserve healthy tissue, aligning with large medical device procurement cycles.

Capital funding Recent financing and a revenue range in the low-to-mid multi-millions indicate growing validation; leverage this to position USMI for larger clinical partnerships, grant-supported trials, and potential co-development deals with oncology-focused manufacturers.

Disruptive tech Unique plasma-based cancer therapy and robotic AI surgical system present a differentiated value proposition; sales outreach should emphasize performance in microscopic tumor cell targeting and tissue-sparing benefits to high-volume cancer centers.

Strategic alliances Collaborations with research institutes (e.g., JCRI-ABTS) suggest openness to academia-driven pilots; pursue joint clinical studies, pilot programs, and sponsored research to unlock deployment in university hospitals and early-access programs.

Scaling readiness Existing tech stack and modest employee base imply potential readiness for partner-facing scalability; propose channel partnerships, distribution agreements, and international regulatory exploration to accelerate market expansion.